By Mill Chart
Last update: Dec 5, 2023
Uncover the potential of ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) as our stock screener's choice for an undervalued stock. NASDAQ:RPRX maintains a strong financial position and offers an appealing valuation. We'll delve into the specifics below.
ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:RPRX boasts a 8 out of 10:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:RPRX was assigned a score of 6 for profitability:
ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:RPRX scores a 5 out of 10:
ChartMill assigns a Growth Rating to every stock. This score ranges from 0 to 10 and evaluates the different growth aspects like EPS and Revenue, both in the past as in the future. NASDAQ:RPRX scores a 4 out of 10:
Our Decent Value screener lists more Decent Value stocks and is updated daily.
For an up to date full fundamental analysis you can check the fundamental report of RPRX
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
ROYALTY PHARMA PLC- CL A
NASDAQ:RPRX (4/23/2024, 8:37:09 AM)
27.56
-0.26 (-0.93%)
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio.
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April.
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s...